BioSpace News Archive

Hopes for a universal cancer vaccine received a boost from a new antigen discovery made by researchers at Arizona State University’s Biodesign Institute.

For the past five years, there have been more than 400 mergers and acquisitions with companies in the gene therapy, immuno-oncology, microbiome and orphan drugs therapeutic space in North America and that trend is likely to continue, according to a new analysis.

Lotus Clinical Research is pleased to announce that two of its Biometrics team members, Jennifer Nezzer and Andrea Krueger, presented at 2019 Veeva R&D Summit to discuss Lotus’ use of Veeva Vault CDMS, which combines EDC, coding, data cleaning, and reporting in a single cloud platform for clinical data management.

BioCardia announced the U.S. commercial availability of its AVANCE™ Bi-Directional Steerable Introducer Sheath for introducing various cardiovascular catheters into the heart, including via the left side of the heart through the interatrial septum.

Retrophin, Inc. announced the appointment of Peter Heerma as chief commercial officer, effective immediately.

ASLAN Pharmaceuticals announced the presentation of new data from a phase 1b open-label, dose escalation study of varlitinib in combination with modified irinotecan and infusional 5-fluorouracil chemotherapy to determine the safety, tolerability and maximum tolerated dose in advanced solid tumours.

Study evaluates clinical utility of 68Ga THP-PSMA PET/CT imaging in men with newly diagnosed and recurrent prostate cancer

Heidelberg Pharma AG announced that it has adjusted its guidance for the current fiscal year published in March 2019.

Industry’s most widely used platform for screening data analysis accelerates Eisai’s novel drug discovery

Ultragenyx Pharmaceutical Inc. announced that Emil Kakkis, the company’s Chief Executive Officer and President will present at the Jefferies Gene Therapy/Editing Summit on Tuesday, October 8, 2019 at 9:45 AM ET in New York, NY.